Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial.
Cognitive function in postmenopausal women receiving letrozole or tamoxifen as adjuvant endocrine treatment was compared during the fifth year of treatment in a substudy of the BIG 1-98 trial. In BIG 1-98 patients were randomized to receive adjuvant (A) 5-years tamoxifen, (B) 5-years letrozole, (C) 2-years tamoxifen followed by 3-years letrozole, or (D) 2-years letrozole followed by 3-years tamoxifen. The primary comparison was the difference in composite score for patients taking letrozole (B+C; N=65) vs. tamoxifen (A+D; N=55). The patients taking letrozole had better overall cognitive function than those taking tamoxifen (difference in mean composite z-scores=0.28, P=0.04, 95% CI: 0.02, 0.54, Cohen's D=0.40 indicating small to moderate effect). In this substudy, breast cancer patients taking adjuvant letrozole during the fifth year of treatment had better cognitive function than those taking tamoxifen, suggesting aromatase inhibitors do not adversely impact cognition compared with tamoxifen.
Phillips
Kelly-Anne
KA
Peter MacCallum Cancer Centre and The University of Melbourne, Melbourne, Victoria, Australia. Kelly.Phillips@petermac.org
Ribi
Karin
K
Sun
Zhuoxin
Z
Stephens
Alisa
A
Thompson
Alastair
A
Harvey
Vernon
V
Thürlimann
Beat
B
Cardoso
Fatima
F
Pagani
Olivia
O
Coates
Alan S
AS
Goldhirsch
Aron
A
Price
Karen N
KN
Gelber
Richard D
RD
Bernhard
Jürg
J
D000368:Aged; D000704:Analysis of Variance; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000523:psychology; D017024:Chemotherapy, Adjuvant; D003071:Cognition / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D017698:Postmenopause; D018709:Statistics, Nonparametric; D013629:Tamoxifen / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D014230:Triazoles / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use
D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D013629:Tamoxifen; D000077289:Letrozole
J Sleep Res. 2003 Dec;12(4):265-74
14633237
Br J Sports Med. 2001 Oct;35(5):297-302
11579059
Cancer. 2008 Nov 1;113(9):2431-9
18823033
Breast Cancer Res Treat. 2005 Aug;92(3):199-206
16155790
N Engl J Med. 2009 Aug 20;361(8):766-76
19692688
Neurosci Res. 2007 Jul;58(3):272-7
17467093
Ann Oncol. 1997 Sep;8(9):825-35
9358933
N Engl J Med. 2005 Dec 29;353(26):2747-57
16382061
Psychooncology. 2004 Jan;13(1):61-6
14745746
Endocr Rev. 2003 Apr;24(2):133-51
12700177
Cancer. 1999 Mar 1;85(5):1186-96
10091805
J Clin Oncol. 2010 Mar 10;28(8):1294-300
20142601
Br J Clin Psychol. 1982 Feb;21(1):1-16
7126941
Neuroscience. 2008 Jan 2;151(1):186-94
18061360
Ann Neurol. 2003 May;53(5):607-15
12730994
Ann Oncol. 2008 Apr;19(4):623-9
17974553
Endocr Rev. 1995 Feb;16(1):35-62
7758432
Psychooncology. 2009 Aug;18(8):811-21
19085975
Support Care Cancer. 2006 Nov;14(11):1111-8
16538498
Hum Psychopharmacol. 2005 Jun;20(4):263-73
15912482
Pharmacol Biochem Behav. 2002 Jan-Feb;71(1-2):269-76
11812532
Menopause. 2007 Nov-Dec;14(6):995-8
17898668
Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):119-28
10581405
Eur J Cancer. 2007 Jun;43(9):1342-7
17499988
Arch Clin Neuropsychol. 2009 Mar;24(2):165-78
19395350
JAMA. 2003 May 28;289(20):2663-72
12771113
J Natl Cancer Inst. 2003 Feb 5;95(3):190-7
12569140
Lancet Oncol. 2008 Oct;9(10):953-61
18768369